Prostaglandin F2α elevates blood pressure and promotes atherosclerosis

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 19, 2009, Pages 7985-7990

  Yu, Ying ^a   Lucitt, Margaret B ^a   Stubbe, Jane ^a   Cheng, Yan ^a   Friis, Ulla G ^b   Hansen, Pernille B ^b   Jensen, Boye L ^b   Smyth, Emer M ^a   FitzGerald, Garret A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Hypertension; Juxtaglomerular granular cell; PGF2 receptor; Renin; Water metabolism

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; CYTOKINE; NITRIC OXIDE; PROSTAGLANDIN F2 ALPHA; INDUCIBLE NITRIC OXIDE SYNTHASE; PROSTAGLANDIN F2ALPHA RECEPTOR; PROSTAGLANDIN RECEPTOR; RENIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CONTROLLED STUDY; HYPERTENSION; HYPOTHALAMUS; KIDNEY COLLECTING TUBULE; MACROPHAGE; MOUSE; NONHUMAN; PLASMA RENIN ACTIVITY; POLYDIPSIA; POLYURIA; PRIORITY JOURNAL; UPREGULATION; URINE OSMOLALITY; ANIMAL; BLOOD PRESSURE; FEMALE; MALE; METABOLISM; MOUSE MUTANT; PHYSIOLOGY;

MUS;

ANIMALS; ATHEROSCLEROSIS; BLOOD PRESSURE; DINOPROST; FEMALE; HYPERTENSION; MACROPHAGES; MALE; MICE; MICE, KNOCKOUT; NITRIC OXIDE SYNTHASE TYPE II; RECEPTORS, PROSTAGLANDIN; RENIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 66049162137     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0811834106     Document Type: Article

References (48)

1. Swales J (1994) Textbook of Hypertension (Blackwell Scientific, Boston).
2. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW (1994) Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 74:1141-1148. (Pubitemid 24176909)
3. Heo HJ, et al. (2007) Endogenous angiotensin II enhances atherogenesis in apoprotein E-deficient mice with renovascular hypertension through activation of vascular smooth muscle cells. Life Sci 80:1057-1063. (Pubitemid 46204724)
4. Knowles JW, et al. (2000) Enhanced atherosclerosis and kidney dysfunction in eNOS(-/-)Apoe(-/-) mice are ameliorated by enalapril treatment. J Clin Invest 105:451-458. (Pubitemid 30127245)
5. Nussberger J, et al. (2008) Renin inhibition by aliskiren prevents atherosclerosis progression: Comparison with irbesartan, atenolol, and amlodipine. Hypertension 51:1306-1311.
6. FitzGerald GA (2002) The choreography of cyclooxygenases in the kidney. J Clin Invest 110:33-34. (Pubitemid 34743462)
7. Qi Z, Hao CM, et al. (2002) Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II. J Clin Invest 110:61-69. (Pubitemid 34743466)
8. Yang T, et al. (2005) Influence of genetic background and gender on hypertension and renal failure in COX-2-deficient mice. Am J Physiol-Renal 288:F1125-1132. (Pubitemid 40677082)
9. Jackson EK, et al. (1981) 6-Keto-prostaglandin E1 is more potent than prostaglandin I2 as a renal vasodilator and renin secretagogue. J Pharmacol Exp Ther 216:24-27. (Pubitemid 11167853)
10. Fitzgerald DJ, Entman SS, Mulloy K, FitzGerald GA (1987) Decreased prostacyclin biosynthesis preceding the clinical manifestation of pregnancy-induced hypertension. Circulation 75:956-963. (Pubitemid 17068524)
11. Fujino T, et al. (2004) Decreased susceptibility to renovascular hypertension in mice lacking the prostaglandin I2 receptor IP. J Clin Invest 114:805-812. (Pubitemid 39578739)
12. Francois H, et al. (2005) Prostacyclin protects against elevated blood pressure and cardiac fibrosis. Cell Metab 2:201-207.
13. Sugimoto Y, et al. (1997) Failure of parturition in mice lacking the prostaglandin F receptor. Science 277:681-683. (Pubitemid 27373912)
14. Saito O, et al. (2003) Expression of the prostaglandin F receptor (FP) gene along the mouse genitourinary tract. Am J Physiol-Renal 284:F1164-1170. (Pubitemid 36578443)
15. Hao CM, Breyer MD (2008) Physiological regulation of prostaglandins in the kidney. Annu Rev Physiol 70:357-377.
16. Takayama K, et al. (2005) Thromboxane A2 and prostaglandin F2alpha mediate inflammatory tachycardia. Nat Med 11:562-566.
17. Brown MJ (2008) Aliskiren. Circulation 118:773-784.
18. Pratt JH (2006) The adrenergic nervous system conversing with the adrenal cortex: new implications for salt-sensitive hypertension. Hypertension 48:820-821. (Pubitemid 44610987)
19. Casellas D, Dupont M, Kaskel FJ, Inagami T, Moore LC (1993) Direct visualization of renin-cell distribution in preglomerular vascular trees dissected from rat kidney. Am J Physiol 265:F151-156. (Pubitemid 23221564)
20. Armstrong RA, Lawrence RA, Jones RL, Wilson NH, Collier A (1989) Functional and ligand binding studies suggest heterogeneity of platelet prostacyclin receptors. Br J Pharmacol 97:657-668. (Pubitemid 19168696)
21. Stjernschantz J, Alm A (1996) Latanoprost as a new horizon in the medical management of glaucoma. Curr Opin Ophthalmol 7:11-17. (Pubitemid 26268823)
22. Sharif NA, Davis TL, Williams GW (1999) [3H]AL-5848 ([3H]9beta-(+)- Fluprostenol). Carboxylic acid of travoprost (AL-6221), a novel FP prostaglandin to study the pharmacology and autoradiographic localization of the FP receptor. J Pharm Pharmacol 51:685-694. (Pubitemid 29346710)
23. Whittle BJ, Oren-Wolman N, Guth PH (1985) Gastric vasoconstrictor actions of leukotriene C4, PGF2 alpha, and thromboxane mimetic U-46619 on rat submucosal microcirculation in vivo. Am J Physiol 248:G580-586. (Pubitemid 15021127)
24. Kiriyama M, et al. (1997) Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol 122:217-224. (Pubitemid 27397191)
25. Abramovitz M, et al. (2000) The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta 1483:285-293. (Pubitemid 30029060)
26. Rouzer CA, et al. (2005) RAW264.7 cells lack prostaglandin-dependent autoregulation of tumor necrosis factor-alpha secretion. J Lipid Res 46:1027-1037. (Pubitemid 43309227)
27. Friis UG, et al. (2005) Prostaglandin E2 EP2 and EP4 receptor activation mediates cAMP-dependent hyperpolarization and exocytosis of renin in juxtaglomerular cells. Am J Physiol-Renal 289:F989-997.
28. Yanai K, et al. (2000) Renin-dependent cardiovascular functions and renin-independent blood-brain barrier functions revealed by renin-deficient mice. J Biol Chem 275:5-8. (Pubitemid 30038945)
29. Kim HS, et al. (1995) Genetic control of blood pressure and the angiotensinogen locus. Proc Natl Acad Sci USA 92:2735-2739.
30. Krege JH, et al. (1995) Male-female differences in fertility and blood pressure in ACE-deficient mice. Nature 375:146-148.
31. Ito M, et al. (1995) Regulation of blood pressure by the type 1A angiotensin II receptor gene. Proc Natl Acad Sci USA 92:3521-3525.
32. Stock JL, et al. (2001) The prostaglandin E2 EP1 receptor mediates pain perception and regulates blood pressure. J Clin Invest 107:325-331. (Pubitemid 32157964)
33. Guan Y, et al. (2007) Antihypertensive effects of selective prostaglandin E2 receptor subtype 1 targeting. J Clin Invest 117:2496-2505. (Pubitemid 47494351)
34. Francois H, Athirakul K, Mao L, Rockman H, Coffman TM (2004) Role for thromboxane receptors in angiotensin-II-induced hypertension. Hypertension 43:364-369. (Pubitemid 38174140)
35. Stier CT, Jr, Roberts LJ, II, Wong PY (1987) Renal response to 9 alpha, 11 beta-prostaglandin F2 in the rat. J Pharmacol Exp Ther 243:487-491. (Pubitemid 18011528)
36. Schweda F, Friis U, Wagner C, Skott O, Kurtz A (2007) Renin release. Physiology 22:310-319.
37. Kurtz A, Wagner C (1999) Cellular control of renin secretion. J Exp Biol 202:219-225. (Pubitemid 29097031)
38. Narumiya S, Sugimoto Y, Ushikubi F (1999) Prostanoid receptors: Structures, properties, and functions. Physiol Rev 79:1193-1226. (Pubitemid 29473315)
39. Morath R, Klein T, Seyberth HW, Nusing RM (1999) Immunolocalization of the four prostaglandin E2 receptor proteins EP1, EP2, EP3, and EP4 in human kidney. J Am Soc Nephrol 10:1851-1860. (Pubitemid 29402505)
40. Jensen BL, Skouv J, Lundholt BK, Lykkesfeldt AE (1999) Differential regulation of specific genes in MCF-7 and the ICI 182780-resistant cell line MCF-7/182R-6. Br J Cancer 79:386-392. (Pubitemid 29046209)
41. Jensen BL, Schmid C, Kurtz A (1996) Prostaglandins stimulate renin secretion and renin mRNA in mouse renal juxtaglomerular cells. Am J Physiol 271:F659-669. (Pubitemid 126757686)
42. Barajas L (1979) Anatomy of the juxtaglomerular apparatus. Am J Physiol 237:F333-343.
43. Taugner R, Buhrle CP, Hackenthal E, Mannek E, Nobiling R (1984) Morphology of the juxtaglomerular apparatus and secretory mechanisms. Contrib Nephrol 43:76-101.
44. Rader DJ, Daugherty A (2008) Translating molecular discoveries into new therapies for atherosclerosis. Nature 451:904-913.
45. Ross R (1999) Atherosclerosis-an inflammatory disease. N Engl J Med 340:115-126.
46. Lu H, Cassis LA, Daugherty A (2007) Atherosclerosis and arterial blood pressure in mice. Curr Drug Targets 8:1181-1189. (Pubitemid 350238919)
47. Wong SL, et al. (2009) Cyclooxygenase-2-derived prostaglandin F2alpha mediates endothelium-dependent contractions in the aortae of hamsters with increased impact during aging. Circ Res 104:228-235.
48. Lu H, et al. (2008) Renin inhibition reduces hypercholesterolemia-induced atherosclerosis in mice. J Clin Invest 118:984-993.